2004 Annual Meeting | Focus on Moderate-to-Severe Alzheimer's Disease

Date Monday 04/26/04

Time 06:30 PM - 09:30 PM Add To Calendar

Session Format This program will be presented both in-person and online

On Demand This program is not expected to be available in the meeting's On Demand product.

Event Type Dinner Seminar

Director(s) Martin R. Farlow, MD, FAAN

Topic(s) Aging/Dementia/Degenerative Disease

Learning Objectives Upon completion:
Participants should be better able to describe cognitive, functional and behavioral decline associated with Alzheimer's disease (AD) progression and the specific manifestations of moderate-to-severe AD; comprehend assessment tools employed in moderate-to-severe AD and their development rationale; manage the behavioral manifestations of moderate-to-severe AD while understanding the importance of combining pharmacologic and non-pharmacologic strategies; review pharmacoeconomic models for AD treatment and evaluate the cost benefit for treating in moderate to severe stages; and critically review limitations and outcomes of controlled trial data in AD.

CME Available No CME available

Program Level Advanced

Recommended Audience Practitioner, Academician, Resident

Event Timeline
07:00 PM - 07:10 PM		Introduction
07:10 PM - 07:40 PM		Moderate to Severe Alzheimer's Disease: General Issues Regarding Assessment and Management Howard Feldman, MD, FAAN
07:40 PM - 08:10 PM		Neuropsychiatric and Behavioral Alterations and Their Management in Late Alzheimer's Disease Jeffrey L. Cummings, MD, FAAN
08:10 PM - 08:35 PM		Cost-consequence and Cost-benefit of Treating Patients with Moderate to Severe Alzheimer's Disease Howard Fillit, MD
08:35 PM - 09:05 PM		The Search for Disease Modification in Moderate to Severe Alzheimer's Disease. A Critical Review of Current Evidence Martin R. Farlow, MD, FAAN
09:05 PM - 09:25 PM		Questions and Answers
09:25 PM - 09:30 PM		Closing Remarks

Faculty Disclosures
Jeffrey L. Cummings, MD, FAAN	Dr. Cummings has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Acadia, Actinogen, Acumen, AlphaCognition, ALZpath, Aprinoia, AriBio, Artery, Biogen, Biohaven, BioVie, BioXcel, Bristol-Myers Squib, Cassava, Cerecin, Diadem, Eisai, GAP Foundation, GemVax, Janssen, Jocasta, Karuna, Lighthouse, Lilly, Lundbeck, LSP/eqt, Mangrove Therapeutics, Merck, NervGen, New Amsterdam, Novo Nordisk, Oligomerix, ONO, Optoceutics, Otsuka, Oxford Brain Diagnostics, Prothena, ReMYND, Roche, Sage Therapeutics, Signant Health, Simcere, sinaptica, Suven, TrueBinding, Vaxxinity, and Wren pharmaceutical, assessment, and investment companies. Dr. Cummings has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Acadia, Biogen, Genentech, Grifols, Janssen, Karuna, Otsuka, reMYND, Roche, Signant Health. Dr. Cummings has stock in Artery, Vaxxinity, Behrens, Alzheon, MedAvante-Prophase, and Acumen. Dr. Cummings has received research support from NIH. Dr. Cummings has received research support from NIGMS. Dr. Cummings has received intellectual property interests from a discovery or technology relating to health care.
Martin R. Farlow, MD, FAAN	No disclosure on file
Howard Fillit, MD	No disclosure on file
	No disclosure on file
Howard Feldman, MD, FAAN	The institution of Dr. Feldman has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Arrowhead Pharmaceuticals. The institution of Dr. Feldman has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Novo Nordisk. The institution of Dr. Feldman has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Janssen Research & Development LLC. The institution of Dr. Feldman has received personal compensation in the range of $5,000-$9,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Roche/Banner/API. The institution of Dr. Feldman has received personal compensation in the range of $10,000-$49,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Tau Consortium. The institution of Dr. Feldman has received research support from US National Institute of Health NIH/NIA. The institution of Dr. Feldman has received research support from US National Institute of Health NIH/NIA. The institution of Dr. Feldman has received research support from Vivoryon Therapeutics. The institution of Dr. Feldman has received research support from US National Institute of Health NIH/NIA. The institution of Dr. Feldman has received research support from US National Institute of Health NIH/NIA. The institution of Dr. Feldman has received research support from LuMind Foundation. The institution of Dr. Feldman has received research support from US National Institute of Health NIH/NIA. The institution of Dr. Feldman has received research support from Biohaven Pharmaceuticals. The institution of Dr. Feldman has received research support from UC San Diego School of Medicine Brain Health Support Program & Sanford Institute for Empathy and Compassion. The institution of Dr. Feldman has received research support from US National Institute of Health NIH/NIA. The institution of Dr. Feldman has received research support from US National Institute of Health NIH/NIA. Dr. Feldman has received intellectual property interests from a discovery or technology relating to health care. Dr. Feldman has a non-compensated relationship as a Medical Advisory Council with Association for Frontotemporal Degeneration (AFTD) that is relevant to AAN interests or activities. Dr. Feldman has a non-compensated relationship as a International Scientific Advisory Board with Translating Research in Elder Care (TREC) that is relevant to AAN interests or activities.

��ɫ��

��ɫ��